"If you want to be entrepreneurial, be bold and let science drive." At this year’s #RegeneronSTS Spectacular Science dinner, RGC®'s Lyndon Mitnaul, PhD, empowered inspiring next-generation innovators to take on society’s biggest challenges.

At Endpoints News #DrugDiscoveryDay, our colleague Cristen Willer, PhD, joined industry leaders to discuss the future of genetic research and discovery. She highlighted Regeneron’s commitment to advancing our understanding of the genetic drivers of disease — in cancer and beyond.

This #MedicalGeneticsAwareness week, we reinforce our commitment to harnessing the power of human genetics for groundbreaking discoveries. From identifying novel targets to accelerating the exploration of new medicines, we’re are pushing the boundaries of what’s possible. 🧬

Delivery is challenging, yet crucial with #GeneticMedicines. We use lipid nanoparticles (LNPs) — microscopic, lipid-based particles that can protect and deliver mRNA to cells — as a tool to precisely target specific cells, with the goal of reaching a range of cells in the body.

This #DNADay, we're opening up our genetics toolbox. From finding targets to optimizing clinical trials — every tool moves science forward. Get a closer look at our approach that’s built for innovation and possibility. 🧬

This week at the @Truveta Symposium, RGCer Marcus Jones shared how combining our robust genetics database with molecular insights like proteomics is, as he said, “helping create a comprehensive dataset that can shift medicine from reactive to proactive.”

We’re live at #ASGCT2025 and ready to talk genetic and cell medicines. From antibody retargeting and immunogenicity to advances in our gene insertion pipeline, we’re digging into the research pushing the science forward. Click through to see more about our latest abstracts.

Our own Nicholas Giovannone has been named a PM360 2025 ELITE 100 honoree! His research began with critical questions in immunology that led him to try to solve the inherent challenge of redosing in AAV-directed gene therapy.

Yesterday we announced our plans to acquire 23andMe. We’re excited to strengthen our leadership in genetics-guided research and prioritize the privacy, security and ethical use of this data. For those just getting to know Regeneron, here’s more about who we are:

At #STATGEN2025, RGCer Jae-Hoon Sul shared how we’re analyzing brain imaging, plasma proteomics and genomic data from the UK Biobank to identify novel biomarkers for neurogenerative diseases. This multi-modal approach aims to accelerate discovery. 🧠

RGCer Adolfo Ferrando presented our scientific program and collaboration model at the II Spanish Congress of Genomic Medicine in Madrid. Leaders from 11 countries brought vibrant enthusiasm and shared optimism—looking forward to more potential conversations and collaborations. 🌍

Last month at #BIO25: CRISPR, RNAi therapeutics and the future of genetic medicines. Regeneron’s Christos Kyratsous shared how we’re advancing genetic medicine platform technologies with the potential to revolutionize how we treat disease. 🧬

At RGC, collaboration fuels scientific discovery. From UK Biobank to Tecnológico de Monterrey to Truveta, we partner with academic and industry collaborators to enhance transparent, representative genetic research on a global scale. 🌍

School’s out, and #science is in. Behind every groundbreaking discovery is a spark of curiosity. This summer, our future scientists got a sneak peek into the world of genomics (and yes, the lab is as cool as it looks). Stay tuned for something exciting this fall…📸!